Marinus Pharmaceuticals News

Marinus Pharmaceuticals Is Maintained at Buy by Truist Securities

Marinus Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow JonesApr 18 07:24 ET

Express News | Marinus Pharmaceuticals Inc : Truist Securities Cuts Target Price to $10 From $25: Truist Securities Cuts Target Price to $10 From $25

Moomoo 24/7Apr 18 06:55 ET

Express News | Marinus Pharmaceuticals Inc : Truist Securities Cuts Target Price to $10 From $25

Moomoo 24/7Apr 17 10:59 ET

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwri

BenzingaApr 17 08:21 ET

Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird

Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird

Dow JonesApr 17 05:24 ET

Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss

Monday, in an interim analysis of Marinus Pharmaceuticals Inc's (NASDAQ:MRNS) phase 3 RAISE trial, evaluating intravenous (IV) ganaxolone as a treatment for refractory status epilepticus (RSE), failed

BenzingaApr 16 14:45 ET

Express News | HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target

Moomoo 24/7Apr 16 10:59 ET

Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics Among Healthcare Movers

Seeking AlphaApr 16 10:00 ET

Express News | Marinus Pharmaceuticals Inc : RBC Cuts Target Price to $3 From $24

Moomoo 24/7Apr 16 02:11 ET

Express News | Marinus Pharmaceuticals Inc : RBC Cuts to Sector Perform From Outperform

Moomoo 24/7Apr 16 02:10 ET

Express News | Marinus Pharmaceuticals Inc : Baird Cuts to Neutral Rating; Cuts Target Price to $2 From $20

Moomoo 24/7Apr 16 01:19 ET

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.

MT NewswiresApr 15 15:59 ET

Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital

Marinus Pharmaceuticals Cut to Sector Perform From Outperform by RBC Capital

Dow JonesApr 15 15:02 ET

Express News | RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3

Moomoo 24/7Apr 15 14:52 ET

Marinus Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 123.96% RBC Capital $24 → $3 Downgrades Outperform → Sector Perform 04/10/2024 1990.33% Cantor

BenzingaApr 15 14:51 ET

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d

BenzingaApr 15 14:11 ET

Trending Stocks Today: Kaival Brands Innovations Shoots up 130%

April 15th - US stocks trending in regular trading hours.Gainers: $Kaival Brands Innovations(KAVL.US)$ shoots up 130% to $6.14 with a turnover of $288.45 million. $Longeveron(LGVN.US)$ surges 51.47% t

moomoo NewsApr 15 14:10 ET

Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health

TipRanksApr 15 13:25 ET

Marinus Pharmaceuticals: A Strong Buy Despite RAISE Trial Setback, With Promising Growth Potential in DEE Market

TipRanksApr 15 13:05 ET

BSGM, ENLV and WISA Among Mid-day Movers

Seeking AlphaApr 15 12:47 ET